ReviewTranslational andrology and urology2015
Inflammation in prostate cancer progression and therapeutic targeting.
Review in Translational andrology and urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 95 citations in OpenAlex.
- Annona crassiflora seed extract modulates histological and molecular markers associated with prostate cancer progression in TRAMP mice.Journal of molecular histology · 2026Article
- Prognostic Value of the SUVmax-IPI Composite Score on Overall Survival in Metastatic Prostate Cancer.Journal of clinical medicine · 2026Article
- Immunosenescence in prostate cancer: from aging-related immune dysfunction to therapeutic opportunities.Frontiers in immunology · 2026Review
- A Narrative Review on Unravelling Bacterial-Mediated Carcinogenesis and Possible Alternative Treatment Strategies.BioMed research international · 2026Review
- Inflammation Beyond the Prostate: The Role of Systemic Inflammatory Disorders in Prostate Carcinogenesis.Cureus · 2025Review
- CAR-T Cell Therapy for Prostate Cancer: Current Advances and Future Perspectives.Biomedicines · 2025Review
- Review
- Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Adiposity Status Close to Diagnosis and Its Association with Prostate Cancer Survival in the UK Biobank.Cancer research communications · 2025Article
- The Urogenital System Microbiota: Is It a New Gamechanger in Urogenital Cancers?Microorganisms · 2025Review
- CHD6 has poly(ADP-ribose)- and DNA-binding domains and regulates PARP1/2-trapping inhibitor sensitivity via abasic site repair.Nature communications · 2025Article
- MiRNAs and tempol therapeutic potential in prostate cancer: a preclinical approach.Journal of molecular histology · 2025Article
- The role of reactive oxygen species in the transformation from prostatitis to prostate cancer: a review.Frontiers in immunology · 2025Review
- Association between inflammatory cytokines and prostate cancer: a bidirectional Mendelian randomization study.Archives of medical science : AMS · 2025Article
- Reprogramming prostate cancer through the microbiome.Frontiers in medicine · 2025Review
- Genetic variants ofInternational journal of medical sciences · 2025Article
- Associations of the Expression Levels and Risk Variants of CDKN2B-AS1 Long Noncoding RNA With the Susceptibility and Progression of Prostate Cancer.Journal of cellular and molecular medicine · 2024Article
- Adiposity assessed close to diagnosis and prostate cancer prognosis in the EPIC study.JNCI cancer spectrum · 2024Article
- The Interplay between Structural Inequality, Allostatic Load, Inflammation, and Cancer in Black Americans: A Narrative Review.Cancers · 2024Review
- Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer.Nature reviews. Urology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chronic inflammation contributes to the onset and progression of human cancer, via modifications in the tumor microenvironment by remodeling the extracellular matrix (ECM) and initiating epithelial mesenchymal transition (EMT). At the biological level, chronically inflamed cells release cytokines that are functionally dictating a constitutively active stroma, promoting tumor growth and metastasis. In prostate cancer, inflammation correlates with increased development of "risk factor" lesions or proliferative inflammatory atrophy (PIA). Chronic inflammation in benign prostate biopsy specimens can be associated with high-grade prostate tumors in adjacent areas. In this article, we discuss the current understanding of the incidence of inflammation in prostate cancer progression and the significance of the process in therapeutic targeting of specific inflammatory signaling pathways and critical effectors during tumor progression. Further understanding of the process of chronic inflammation in prostate tumor progression to metastasis will enable development and optimization of novel therapeutic modalities for the treatment of high-risk patients with advanced disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.